ipilimumab

Ligand id: 6888

Name: ipilimumab

References
1. Davis T, Keler T, Graziano R, Korman AJ. (2012)
Methods of treatement using ctla-4 antibodies.
Patent number: EP1503794. Assignee: Medarex, Inc.. Priority date: 12/04/2002. Publication date: 19/09/2012.
2. FDA. 
Nivolumab in combination with ipilimumab.
Accessed on 17/06/2016. Modified on 17/06/2016. US Food and Drug Administration, http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm465274.htm
3. Halk EL, Korman AJ, Lonberg N. (2001)
Human ctla-4 antibodies and their uses.
Patent number: WO2001014424. Assignee: Medarex Inc. Priority date: 24/08/1999. Publication date: 01/03/2001.
4. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P et al.. (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
N. Engl. J. Med.373 (1): 23-34. [PMID:26027431]
5. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS et al.. (2015)
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
N. Engl. J. Med.372 (21): 2006-17. [PMID:25891304]